Affimed N.V. · OTC:AFMDQ
Affimed — Investor Presentation (March 2020)
22 slides from Affimed's investor presentation, March 2020
Slide 1: Actualizing the Untapped Potential of the Innate Immune System
Actualizing the Untapped Potential of the Innate Immune System Affimed’s Approach to Advancing Immuno-oncology
Slide 2: Forward-Looking Statements / Cautionary Note
Forward-Looking Statements / Cautionary Note This presentation and the accompanying oral commentary contain “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral
Slide 3: Every Patient Deserves More Options. Every Patient Deserves Another Chance.
Every Patient Deserves More Options. Every Patient Deserves Another Chance. The first patient to receive AFM13 to treat CD30+ lymphoma with cutaneous presentation CONFIDENTIAL 3
Slide 4: Leading Innate Immunity Activation to Treating Cancer Patients
Leading Innate Immunity Activation to Treating Cancer Patients Innate immune cell activation Broad pipeline comprising fully represents a compelling Late-stage company owned and partnered programs opportunity in oncology ✓ Industry-leading, ROCK® antibody ✓ First patient dosed in AFM13 ✓ AFM24: clin
Slide 5: Our Pipeline: Versatile Innate Cell Engagers Targeting Hematologic and Solid Tumors
Our Pipeline: Versatile Innate Cell Engagers (ICEs) Targeting Hematologic and Solid Tumors AFM13 (Tumor Target CD30) Preclinical Phase 1 Phase 2 Peripheral T-cell lymphoma (AFM13-202) Registration Directed, Enrolling Transformed mycosis fungoides (AFM13-202) POC, Enrolling CD30-positive T-cell lymph
Slide 6: Affimed's ICEs Activate the Innate Immune System and Trigger Anti-Tumoral Response
Affimed’s ICEs Activate the Innate Immune System and Trigger a Concerted Anti-Tumoral Immune Response Multiple Therapeutic Approaches Innate Immunity Macrophage First Line of Defense Adoptive NK & CAR- Monotherapy NK Cell Combinations NK cell ICE Dendritic cell ICEs ICE Adaptive Immunity Second Line
Slide 7: ICEs from the ROCK Platform are Optimized for Anti-Cancer Activity
ICEs from the ROCK® Platform are Optimized for Anti-Cancer Activity ROCK® platform builds therapeutics customized to tumor targets ROCK® Platform Innate Cell Engagers (ICEs) Human IgG1 ICE CD16A receptor NK cell or macrophage Multivalent antibodies with modular architecture ▪ Tunable affinities and
Slide 8: Innate Cell Engager for CD30+ Lymphomas
Innate Cell Engager for CD16A CD30+ Lymphomas target Treatment with AFM13 CD30 target
Slide 9: Patients with CD30+ Lymphomas Need More Treatment Options
Patients with CD30+ Lymphomas Need More Treatment Options Market Potential (US, Annual) Adcetris WW annual revenue projected PTCL ▪ Lack of standard of care in R/R – high Peripheral to exceed $1B in 2019 ~2,700 unmet need – accelerated approval path T-cell Lymphoma eligible patients given lack of op
Slide 10: AFM13: Holds Promise as Monotherapy and in Combination
AFM13: Holds Promise as Monotherapy and in Combination with allo-NK Cells or Anti-PD-1 Antibodies Today 2018 2019 2020 2021+ AFM13 T-cell Lymphoma AFM13-102: monotherapy Market CD30 / CD16A Fast to R/R PTCL and CTCL AFM13-202 (REDIRECT): monotherapy R/R PTCL and TMF 1L PTCL Ph 3: Confirmatory study
Slide 11: AFM13: Delivering Meaningful Benefit to Patients with CD30+ Lymphomas
AFM13: Delivering Meaningful Benefit to Patients with CD30+ Lymphomas Monotherapy Combinations w/ Adoptive NK & CAR-NK Cell Other I-O Agents Combinations AFM13: First-in-class innate cell Shows promising signs of broad Combination with adoptive transfer of innate engager targeting patients clinical
Slide 12: AFM13: Late-Stage Opportunity with Broad Expansion Potential Across CD30+ Lymphomas
AFM13: Late-Stage Opportunity with Broad Expansion Potential Across CD30+ Lymphomas Near-term revenue opportunity ~2,700 US patients Accelerated approval potential in: ▪ PTCL, R/R ▪ TMF, R/R Revenue expansion potential ~10,000+ US patients ▪ PTCL, 1L ▪ CD30+ lymphomas – NK cell therapy combination ▪
Slide 13: Innate Cell Engagers in Solid Tumors
Innate Cell Engagers CD16A in Solid Tumors target Treatment with AFM24 EGFR target
Slide 14: AFM24 (EGFR/CD16A): Potential to Disrupt the Treatment Paradigm
AFM24 (EGFR/CD16A): Potential to Disrupt the Treatment Paradigm for Patients with EGFR-Expressing Tumors AFM24 ▪ Novel MOA targeting EGFR tumors with the potential to improve EGFR / CD16A the standard-of-care ▪ Favorable toxicity profile: unlike cetuximab, no skin toxicity in cyno toxicity studies ▪
Slide 15: AFM24 (EGFR/CD16A): Potential to Disrupt the Treatment Paradigm
AFM24 (EGFR/CD16A): Potential to Disrupt the Treatment Paradigm for Patients with EGFR-Expressing Tumors AFM24 holds the promise of: Based on preclinical data: ✓ Opportunity for improved outcomes ✓ Differentiated antibody profile • Efficacy of current therapies rely on mAb inhibition • New MOA with
Slide 16: A Multipronged Clinical Development Strategy for AFM24
A Multipronged Clinical Development Strategy Designed to Deliver AFM24 to Those Patients with Few Options Initial Opportunities Future Potential Initiated 1Q20 Expansion cohorts Colorectal 3L All-comers 2L All-comers, Wild Type and Mutated Cancer Phase 1 Non-small All-comers, Cell Lung 3L All-comers
Slide 17: Pipeline Expansion
CD16A Pipeline Expansion target AFM28, AFM32 and partnered programs TAA
Slide 18: Vast Pipeline Opportunities for ROCK Platform
Vast Pipeline Opportunities for ROCK® Platform Partnering New ICEs Rational Combinations ▪ Adoptive NK cells ▪ Checkpoint inhibitors (anti-PD-1 and beyond) ▪ Targeted cytokines ▪ Other innate and adaptive MOAs synergistic CD16A Tumor Targets to innate cell engagement • AFM28 and AFM32 – wholly owned
Slide 19: Upcoming Anticipated Milestones
Upcoming Anticipated Milestones 2019 2020 2021 2022 Initiated registration-directed Ph 2 study in PTCL and POC POC data in PTCL and TMF Progress update in PTCL and LPI and top line data in PTCL study in TMF in Q4 TMF AFM13 Update on progress (study Safety and initial efficacy POC data for AFM13+aNK
Slide 20: We Are a Clinical-Stage Organization Comprised of Innate Immunity Experts
We Are a Clinical-Stage Organization Comprised of Innate Immunity Experts Dedicated to Delivering Meaningful Therapeutics PRODUCTS FIT-FOR-PURPOSE ROCK® PLATFORM • Multiple innate cell engagers • Customizable innate cell engager targeting hematologic and platform with proprietary solid tumors CD16A
Slide 21: Leading Innate Immunity Activation to Treating Cancer Patients
Leading Innate Immunity Activation to Treating Cancer Patients Innate immune cell activation Broad pipeline comprising fully represents a compelling Late-stage company owned and partnered programs opportunity in oncology ✓ Industry-leading, ROCK® antibody ✓ First patient dosed in AFM13 ✓ AFM24: clin
Slide 22: Thank you
T 1 affi Tred Thank you